Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.

ABSTRACT:

Importance

Case-based surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection likely underestimates the true prevalence of infections. Large-scale seroprevalence surveys can better estimate infection across many geographic regions.

Objective

To estimate the prevalence of persons with SARS-CoV-2 antibodies using residual sera from commercial laboratories across the US and assess changes over time.

Design, setting, and participants

This repeated, cross-sectional study conducted across all 50 states, the District of Columbia, and Puerto Rico used a convenience sample of residual serum specimens provided by persons of all ages that were originally submitted for routine screening or clinical management from 2 private clinical commercial labor

SUBMITTER: Bajema KL 

PROVIDER: S-EPMC7686880 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature